Report on the Clinical Efficacy of CTX-712 in Ovarian and Hematologic Cancers
First written in FY2024-Q3. 7 of 10 entries say "Advanced", first in FY2025. Latest entry: 2026-10-15.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Based on data from the 42 patients treated to date, the Safety Evaluation Committee confirmed a dosage and administration regimen meeting the safety and efficacy criteria for transition to an expansion cohort.」
Based on data from 42 patients treated with rogocekib, a dosage and administration regimen meeting the safety and efficacy criteria for transition to an expansion cohort was confirmed. - FY2025AdvancedAnnual report
「Of these, among the 4 patients with Splicing Factor mutations, responses were observed in 3 patients (75%). Of the patients who achieved a response, 3 had durable responses lasting 300 days or longer, including 1 patient with a response lasting 974 days.」
In addition to previously reported response data for rogocekib, a 75% response rate among patients with Splicing Factor mutations and response durations of 300 days or longer, including a maximum of 974 days, were newly reported. - FY2024RestatedAnnual report
「Regarding efficacy, 4 partial responses (PRs) were observed in patients with solid tumors, all of which were ovarian cancer cases (4/14 cases, 28.6%). Among patients with ovarian cancer harboring Myc amplification, 2 of 3 patients (66.7%) achieved a PR. Among 14 patients with AML and MDS combined, 4 complete remissions (CRs), 1 complete remission with incomplete hematologic recovery (CRi), and 1 morphologic leukemia-free state (MLFS) were observed, resulting in an Overall Response Rate of 42.9%.」
Response data for CTX-712 in ovarian and hematologic cancers continues to be reported in the full-year results. - FY2024-Q3First statedAnnual report
「Regarding efficacy, 4 partial responses (PRs) were observed in patients with solid tumors, all of which were ovarian cancer cases (4/14 cases, 28.6%). Among patients with ovarian cancer harboring Myc amplification, 2 of 3 patients (66.7%) achieved a PR. Among 14 patients with AML and MDS combined, 4 complete remissions (CRs), 1 complete remission with incomplete hematologic recovery (CRi), and 1 morphologic leukemia-free state (MLFS) were observed, resulting in an Overall Response Rate of 42.9%.」
Clinical data on responses, response rates and complete remissions observed in the Phase 1 trial are presented.